Glycylglycyl-L-leucine

We are Glycylglycyl-L-leucine CAS:14857-82-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: Glycylglycyl-L-leucine
CAS.NO:14857-82-0
Molecular Formula:C10H19N3O4
Molecular Weight:245.27600

Synonyms:
glycyl-glycyl-leucine
L-Leucine, glycylglycyl-
Glycylglycyl-L-leucine
REF DUPL: H-Gly-Gly-Leu-OH
GLYCYL-GLYCYL-L-LEUCINE
Gly-Gly-Len
H-GLY-GLY-LEU-OH
GLYCYL-GLYCY-L-LEUCINE extrapure
GLY-GLY-LEU

Physical and Chemical Properties:
Density: 1.199 g / cm3
Boiling point: 573.7ºC at 760 mmHg
Flash point: 300.8ºC
Refractive index: 1.504

Specification:
Appearance: White or Off-white Powder
Purity:≥98%
Total Impurity:≤2.0%

Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -20ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.

Glycylglycyl-L-leucine


Related News: Australia has started denying entry to all travelers who have come from or transited through mainland China.dodecil prop-2-enoato CAS:2156-97-0 This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body.622-59-3 This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body.1-etil-7-nitro-1,2,3,4-tetrahidroquinolina CAS:57883-28-0 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
H-Tyr-Asp-OH View Details
(2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate View Details
2-(3,5-Di-Tert-Butyl-2-Hydroxyphenyl)-5-Chlorobenzotriazole View Details
N-(Triphenylmethyl)-5-(4-Bromomethylbiphenyl-2-yl-)Tetrazole manufacturer 3-Iodo-4-fluorobromobenzene manufacturer 4-Chloro-3-nitrotoluene manufacturer 2,5-Difluoropyridine manufacturer 5-Fluoroisatin manufacturer